Gilead Sciences (GILD) Competitors

Gilead Sciences has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Gilead Sciences currently has a consensus price target of $158.04, indicating a potential upside of 16.31%. Ligand Pharmaceuticals has a consensus price target of $336.57, indicating a potential upside of 14.77%. Given Gilead Sciences' higher probable upside, equities research analysts clearly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

In the previous week, Gilead Sciences had 13 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 34 mentions for Gilead Sciences and 21 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.82 beat Ligand Pharmaceuticals' score of 0.55 indicating that Gilead Sciences is being referred to more favorably in the media.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Gilead Sciences' net margin of -10.64%. Ligand Pharmaceuticals' return on equity of 20.06% beat Gilead Sciences' return on equity.

Moderna presently has a consensus price target of $42.13, indicating a potential downside of 33.83%. Gilead Sciences has a consensus price target of $158.04, indicating a potential upside of 16.31%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Moderna.

In the previous week, Gilead Sciences had 3 more articles in the media than Moderna. MarketBeat recorded 34 mentions for Gilead Sciences and 31 mentions for Moderna. Gilead Sciences' average media sentiment score of 0.82 beat Moderna's score of 0.40 indicating that Gilead Sciences is being referred to more favorably in the news media.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Gilead Sciences has a net margin of -10.64% compared to Moderna's net margin of -141.43%. Gilead Sciences' return on equity of -2.11% beat Moderna's return on equity.

Gilead Sciences has higher revenue and earnings than Moderna. Gilead Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 4 more articles in the media than Gilead Sciences. MarketBeat recorded 38 mentions for Regeneron Pharmaceuticals and 34 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.82 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Gilead Sciences is being referred to more favorably in the media.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences currently has a consensus price target of $158.04, indicating a potential upside of 16.31%. Regeneron Pharmaceuticals has a consensus price target of $797.75, indicating a potential downside of 0.03%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vir Biotechnology presently has a consensus target price of $20.63, indicating a potential upside of 130.19%. Gilead Sciences has a consensus target price of $158.04, indicating a potential upside of 16.31%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Gilead Sciences.

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Gilead Sciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

In the previous week, Gilead Sciences had 13 more articles in the media than Vir Biotechnology. MarketBeat recorded 34 mentions for Gilead Sciences and 21 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 0.82 beat Vir Biotechnology's score of -0.17 indicating that Gilead Sciences is being referred to more favorably in the news media.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vir Biotechnology has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Gilead Sciences has a net margin of -10.64% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of -2.11% beat Vir Biotechnology's return on equity.